ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the acceptance of an abstract with the results of its expanded access program (EAP) evaluating eryaspase in acute lymphoblastic leukemia (ALL) for poster presentation at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting, which will be held from December 11-14, 2021, both in Atlanta, Georgia and virtually.